Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China; Hunan Provincial Clinical Research Center for Respiratory Diseases, Changsha, China.
Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China; Hunan Provincial Clinical Research Center for Respiratory Diseases, Changsha, China; Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China; Key Laboratory of Molecular Radiation Oncology of Hunan Province, Changsha, China. Email:
Ann Palliat Med. 2021 Jan;10(1):202-209. doi: 10.21037/apm-20-2229.
Recent clinical studies have reported that some cytokines are associated with lung cancer prognosis and mortality. However, the relationship between cytokines and clinical outcomes in severe lung cancer patients was unclear. IL-6 as an important cytokine in inflammation, expression level in severe lung cancer patients was unknown.
A cohort of 55 severe lung cancer patients were enrolled retrospectively in this study. The clinical characteristics, including performance status (PS), therapeutic effect, and patients' adverse effects, were recorded. The association of cytokines and the concerned clinical outcomes were assessed by logistic regression analysis. The area under the curve (AUC) was assessed to evaluate the strength of prediction.
The mean age of the patients was 59.8, and 42 patents were males. Increased IL-6 levels were associated with worse PS. Logistic regression analysis demonstrated that higher IL-6 was associated with an increased risk of progressive disease (PD) (OR =1.03, 95% CI: 1.0-1.06). The area under the ROC curve (AUC) of the model used for predicting PD was 0.821.
Increased IL-6 levels are correlated with worse PS and are an essential predictor for PD in severe lung cancer patients. Monitoring the IL-6 level may represent an essential strategy in improving the prognosis of patients with severe lung cancer.
最近的临床研究报告称，一些细胞因子与肺癌的预后和死亡率有关。然而，细胞因子与重症肺癌患者临床结局之间的关系尚不清楚。IL-6 作为炎症中的一种重要细胞因子，其在重症肺癌患者中的表达水平尚不清楚。
本研究回顾性纳入了 55 例重症肺癌患者。记录了患者的临床特征，包括体能状态（PS）、治疗效果和不良反应等。采用逻辑回归分析评估细胞因子与相关临床结局的关系。采用曲线下面积（AUC）评估预测能力。
患者的平均年龄为 59.8 岁，42 例为男性。IL-6 水平升高与 PS 较差相关。逻辑回归分析表明，IL-6 水平升高与疾病进展（PD）的风险增加相关（OR=1.03，95%CI：1.0-1.06）。用于预测 PD 的模型的 AUC 为 0.821。
IL-6 水平升高与 PS 较差相关，是重症肺癌患者 PD 的重要预测指标。监测 IL-6 水平可能是改善重症肺癌患者预后的重要策略。
